Immunopurification of Human Factor VIII/vWF Complex from Plasma

Summary

In this study we describe a process for immunopurification of FVIII/vWF complex directly from plasma. A mAb against vWF has been selected that is able to bind, under physiologic conditions, the FVIII/vWF complex and to release it in slightly alkaline conditions while preserving its activity.

After investigating the influence of solid supports and of coupling methods on the recovery of active FVIII we produced an immunoadsorbent by immobilisation of the selected mAb onto a Sephacryl S-1000 support using a benzoquinone coupling method. With this immunoadsorbent we developed a purification process directly from plasma with an excellent recovery (50%) of both FVIII and vWF activities. The product obtained is very enriched (the FVIII: C specific activity is 20 IU/mg of protein) and is stable after lyophilization.

Keywords

Factor VIII - von Willebrand factor - Monoclonal antibodies - Immunopurification - Immunoadsorbent

• References

• 1 Chavin SI. Factor VIII: structure and function in blood clotting. Am J Hematol 1984; 16: 297-306
• 2 Owen WG, Wagner RH. Antihemophilic factor: separation of an active fragment following dissociation by salts or detergents. Thromb Diath Haemorrh 1972; 27: 502-515
• 3 Hoyer LW. Molecular pathology and immunology of factor VIII (hemophilia A and factor VIII inhibitors). Hum Pathol 1987; 18: 153-161
• 4 Weiss HJ, Sussman II, Hoyer LW. Stabilization of Factor VIII in plasma by the von Willebrand factor. J Clin Invest 1977; 60: 390-404
• 5 Fay PJ, Cavallaro C, Marder VJ. Brief communication: comparison of the in vivo survival of human factor VIII with and without von Willebrand factor in the hemophilic dog. Thromb Res 1986; 37: 425-429
• 6 Gitshier J, Wood WI, Goralka TM, Wion KL, Chen EY, Eaton DH, Vehar GA, Capon DJ, Lawn RM. Characterization of the human factor VIII gene. Nature 1984; 312: 326-330
• 7 Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett WG, Foster WB, Coe ML, Knutson GJ, Fass DN, Hewick RM. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-347
• 8 Vehar GA, Keyt B, Eaton D, Rodriguez H, O’Brien DP, Rotblat F, Opperman H, Keck R, Wood WI, Hardins RN, Tuddenham EGD, Lawn RM, Capon DJ. Structure of human factor VIII. Nature 1984; 312: 337-342
• 9 Wood WI, Capon DJ, Simonsen CC, Eaton DL, Gitshier J, Keyt B, Seeburg PH, Smith DH, Hollingshead P, Wion KL, Delwart E, Tuddenham EGD, Vehar GA, Lawn RM. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-337
• 10 Atichartakarn V, Marder VJ, Kirby EP, Budzynski AZ. Effects of enzymatic degradation on the subunit composition and biologic properties of human factor VIII. Blood 1978; 51: 281-297
• 11 Andersson LO, Forsman N, Huang K, Larsen K, Lundin A, Pavlu B, Sandberg H, Sewerin K, Smart J. Isolation and characterization of human Factor VIII: Molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma. Proc Natl Acad Sci USA 1986; 83: 2979-2985
• 12 Eaton DL, Wood WI, Eaton D, Hass PE, Hollingshead P, Wion K, Mather J, Lawn RM, Vehar GA, Gorman C. Construction and characterization of an active factor VIII variant lacking the central one third of the molecule. Biochemistry 1986; 26: 8342-8347
• 13 Fay PJ, Anderson MT, Chavin SI, Marder VJ. The size of human factor VIII heterodimers and the effects produced by thrombin. Biochim Biophys Acta 1986; 871: 268-278
• 14 Sadler JE, Shelton-Inloes BB, Sorace JM, Harlan JM, Titani K, Davie EW. Cloning and characterization of two cDNAs coding for human von Willebrand factor. Proc Natl Acad Sci USA 1985; 82: 6394-6398
• 15 Fretto LJ, Fowler WE, Mc Caslin DR, Ericksson HP, Mc Kee PA. Substructure of human von Willebrand Factor. J Biol Chem 1986; 261: 15679-15689
• 16 Furlan M. Factor VIII/von Willebrand factor: a multivalent ligand binding to platelets and collagen. Blut 1986; 52: 329-336
• 17 Davies BL, Furlong RA, Peake IR. Studies on the relationship between factor VIII-related antigen (VIII :RAg) and factor VIII clotting antigen (VIII :CAg) by Immunoelectrophoresis and autoradiography using ¹²⁵I anti-VIII:CAg. Thromb Res 1981; 22: 87-93
• 18 Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 1987; 262: 8443-8446
• 19 Pool JG, Shannon AE. Production of high purity concentrates of anti-hemophilic globulin in a closed bag system. N Engl J Med 1965; 273: 1443
• 20 Johnson AJ, Karpatkin MH, Newman J. Preparation of and clinical experience with antihemophilic factor concentrates. Thromb Diath Haemorr 1969; suppl (Suppl. 35) 49
• 21 Brinkhous KM, Shanbrom E, Roberts HR, Webster WP, Fekete L, Wagner RH. A new high potency glycine-precipitated antihemophilic factor (AHF) concentrate. J Am Med Assoc 1968; 205: 613-617
• 22 Perret BA, Furlan M, Beck EA. Studies on factor VIII-related protein II. Estimation of molecular size differences between factor VIII oligomers. Biochim Biophys Acta 1979; 578: 164
• 23 Austen DE G. The chromatographic separation of factor VIII on aminohexyl Sepharose. Br J Haematol 1979; 43: 669-674
• 24 Griffith M, Liu S, Neslund G, Tsang I, Lettelier D, Berkebile R. Preparation of high specific activity plasma AHF by anti-FVIII:C immunoaffinitÿ chromatography XIth International Congress on Thrombosis and Haemostasis, Bruxelles. 04.07.1987
• 25 Tuddenham EGD, Trabold NC, Collins JA, Hoyer LW. The properties of factor VIII coagulant activity prepared by immunosorbent chromatography. J Lab Clin Med 1979; 93: 40-53
• 26 Fulcher CA, Zimmerman TS. Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody. Proc Natl Acad Sci USA 1982; 79: 1648-1652
• 27 Stel HV, Veerman ECI, Huisman JG, Janssen MC, Van Mourik JA. A rapid one-step immunoradiometric assay for factor VIII-procoagulant antigen utilizing monoclonal antibodies. Thromb Haemostas 1983; 50: 860-863
• 28 Sultan Y, Avner P, Maisonneuve P, Arnaud D, Jeanneau C. An immunoradiometric assay for factor VIII related antigen (VIIIRAg) using two monoclonal antibodies. Comparison with polyclonal rabbit antibodies for use in von Willebrand’s disease diagnosis Thromb Haemostas 1984; 52: 250-252
• 29 Soulier JP, Larrieu MJ. Nouvelle méthode de diagnostic de l’hémophilie. Dosage des facteurs antihémophiliques A et B. Le sang 1953; 24: 205
• 30 Kirwood TB L, Barrowcliffe TW. Discrepancy between one-stage and two-stage assay of factor VIII :C. Br J Haematol 1978; 40: 333
• 31 Howard MA, Firkin BG. Ristocetin, a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971; 26: 362-369
• 32 Mazurier C, Parquet-Gernez A, Samor B, Goudemand M, Montreuil J. Etude de l’antigène lié au facteur VIII (FVIIIR: Ag) Purification par Chromatographie d’immuno-affinité. C R Acad Sci Paris 1979; 296: 257
• 33 Köhler G, Milstein C. Continuous cultured of fused cell secreting antibody of predefined specificity. Nature 1975; 256: 495
• 34 Sola B, Avner P, Sultan Y, Jeanneau C, Maisonneuve P. Monoclonal antibodies against human factor FVIII molecule neutralize antihemophilic factor and ristocetin cofactor activities. Proc Natl Acad Sci 1982; 79: 183-187
• 35 Scatchard G. The attraction of proteins to small molecules and ions. Ann N Y Acad Sci 1949; 51: 660
• 36 Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgG₁ IgG_2a and IgG_2b immunoglobulins from mouse serum using protein A-Sepha-rose. Immunochemistry 1978; 15: 429-436
• 37 Weston PD, Avrameas S. Proteins coupled to polyacrylamide beads using glutaraldehyde. Biochem Biophys Res Commun 1971; 45: 1574
• 38 Axen R, Porath J, Ernback S. Chemical coupling of peptides and proteins to polysaccharides by means of cyanogen halides. Nature 1967; 214: 1302
• 39 Cuatrecasas P. Protein purification by affinity chromatography. J Biol Chem 1970; 245: 574
• 40 Porath J, Fornstedt N. Group fractionation of plasma proteins on dipolar ion exchangers. J Chromatogr 1970; 51: 479-489
• 41 Nillson K, Mosbach K. Immobilization of enzymes and affinity ligands to various hydroxyl group carrying supports using highly reactive sulfonyl chlorides. Biochem Biophys Res Commun 1981; 102: 449
• 42 Finlay TH, Troll V, Levy M, Johnson A, Hodgins LT. New methods for the preparation of biospecific adsorbents and immobilized enzymes utilizing trichloro-s-triazine. Anal Biochem 1978; 87: 77
• 43 Brandt J, Andersson LO, Porath J. Covalent attachement of proteins to polysaccharide carriers by means of benzoquinone. Biochim Biophys Acta 1975; 386: 196-202
• 44 Brocway W, Fass DN. The nature of the interaction between ristocetin-Willebrand factor and the factor VIII coagulant activity molecule. J Lab Clin Med 1977; 89: 1295-1305
• 45 Hoyer LW. The factor VIII complex: structure and function. Blood 1981; 58: 01-13
• 46 Hornsey VS, Griffin BD, Pepper DS, Micklem LR, Prowse CV. Immunoaffinity purification of factor VIII complex. Thromb Haemostas 1987; 57: 102-105
• 47 Jorieux S, Mazurier C, Deromeuf C, Goudemand M. Properties and interests of a monoclonal antibody to human von Willebrand factor, abstract 14. Bari International Conference on Factor VIII/von Willebrand Factor. 10..1985
• 48 Fass DN, Knutson GJ, Katzmann JA. Monoclonal antibodies to porcine factor VIII coagulant and their use in the isolation of active coagulant protein. Blood 1982; 59: 594-600